While rare, more serious potential side effects include pancreatitis, gallbladder problems, kidney issues, allergic reactions and hypoglycemia (especially when used with other diabetes medications)
Wegovy is specifically licensed for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
Avoid increased amounts of artificial food coloring, as it may increase the chances of black spots in stool
Clinical and Practical Considerations Diabetes providers familiar with GLP1 agonists like semaglutide and liraglutide must now consider broader eligibility
Review the trial page date, recruitment status, site location, and study contact details
Advances in the management of diabetes mellitus: a focus on personalized medicine